Group 1 - The core point of the announcement is that Shandong Weigao Blood Purification Products Co., Ltd. has approved a capital increase in its joint venture, Weigao Taiermao (Weihai) Medical Products Co., Ltd., to support the development of peritoneal dialysis fluid business [3][9][14] - The board meeting was held on November 20, 2025, with all nine directors present, and the decision-making process complied with relevant laws and regulations [2][5][16] - The company plans to invest 72.5 million RMB in the joint venture, increasing its registered capital from 160 million RMB to 305 million RMB, while maintaining a 50% ownership stake [8][9][14] Group 2 - The capital increase is part of the company's strategic planning and aims to meet the needs of its peritoneal dialysis fluid business [8][14] - The transaction does not constitute a major asset restructuring and has been approved by the independent directors and the board of directors [9][15][17] - The joint venture's ownership structure remains unchanged, with both the company and Taiermao China holding 50% each [10][14]
山东威高血液净化制品股份有限公司 第二届董事会第十八次会议决议公告